According to Bloomberg, the six analysts that follow COMPASS Pathways plc (NASDAQ: CMPS) have given the company an average rating of “Buy” the stock. The rating was given because some analysts believe the company’s stock price will go up shortly. There have been five separate analyses that have concluded that investors should buy the stock.
The year before, brokerages predicted that prices would average $74.33 the following year. Many research firms have made their CMPS studies accessible to the general public. In research published on Friday, August 5th, Citigroup decreased their price objective for COMPASS Pathways from $49.00 to $46,000. Even though this modification took place, the company continued to advocate purchasing the business.
Cantor Fitzgerald dropped their price objective for COMPASS Pathways from $58.00 to $35.00 in a research note that was made public on Friday, August 5th. NASDAQ: CMPS started trading on Tuesday for $16.99. The first day of trading was on Tuesday. The price of the stock’s moving average over the previous 50 days comes in at $14.67, while the moving average over the past 200 days comes in at $12.44.
The price of COMPASS Pathways stock hit a low of $6.54 over the 52 weeks, while it reached a high of $49.51 during the same period. The company has a P/E ratio of 8.54, its beta value sits at 2.54, and its market capitalization is now sitting at $722.45 million.
In recent months, several well-known investors have made adjustments to the current interests in CMPS they are now holding. Raymond James & Associates invested in COMPASS Pathways throughout the final three months of 2018, which resulted in $731,000.
A donation of 120,000 USD was made to COMPASS Pathways by Advanced Research Investment Solutions LLC throughout the final three months of 2018. During the fourth period of the quarter, Alps Advisors Inc. provided COMPASS Pathways with an investment of a total of 1,067,000 dollars. A contribution of $660,000 was made to COMPASS Pathways by Qube Research & Technologies Ltd. during the last three months of 2018.
A $5,945,000 payment to COMPASS Pathways during the fourth quarter by CQS US LLC should not be considered last. To the tune of 17.86% of the company’s stock, institutional investors and hedge funds collectively hold the company’s shares. Providing mental health services is the primary focus of COMPASS Pathways plc’s operations in the United Kingdom and the United States of America. Comp360, a medication containing psilocybin, is currently undergoing clinical testing in Phase II to treat post-traumatic stress disorder (PTSD).
Depression patients who did not react to treatment were the focus of clinical trials in the phase IIb stage.
